BSE Live
Apr 21, 10:33Prev. Close
274.55
Open Price
283.90
Bid Price (Qty.)
271.05 (6)
Offer Price (Qty.)
275.00 (1)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Profit & Loss account of Everest Organics (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 159.48 | 226.49 | 208.73 | 230.22 | 207.36 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 29.25 | 25.69 | 30.17 | 25.79 | |
| Revenue From Operations [Net] | 159.48 | 197.24 | 183.05 | 200.05 | 181.57 | |
| Total Operating Revenues | 159.48 | 197.24 | 183.05 | 200.05 | 181.57 | |
| Other Income | 0.69 | 0.89 | 6.94 | 2.21 | 1.06 | |
| Total Revenue | 160.17 | 198.13 | 189.99 | 202.26 | 182.63 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 97.50 | 123.41 | 124.90 | 140.36 | 115.99 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 30.66 | 32.44 | 30.38 | 26.17 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 1.04 | 0.56 | -3.23 | -4.51 | -8.22 | |
| Employee Benefit Expenses | 16.35 | 18.80 | 16.30 | 16.33 | 15.26 | |
| Finance Costs | 5.19 | 5.47 | 3.31 | 3.10 | 3.26 | |
| Depreciation And Amortisation Expenses | 5.96 | 5.80 | 4.47 | 3.80 | 3.37 | |
| Other Expenses | 37.36 | 12.83 | 11.70 | 11.07 | 9.52 | |
| Total Expenses | 163.41 | 197.52 | 189.90 | 200.52 | 165.35 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | -3.24 | 0.61 | 0.09 | 1.74 | 17.27 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | -3.24 | 0.61 | 0.09 | 1.74 | 17.27 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.00 | 0.10 | 0.02 | 0.29 | 3.02 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -1.95 | 0.37 | 0.26 | 0.31 | 0.54 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | -1.95 | 0.47 | 0.27 | 0.60 | 3.56 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | -1.29 | 0.14 | -0.18 | 1.14 | 13.71 | |
| Profit/Loss From Continuing Operations | -1.29 | 0.14 | -0.18 | 1.14 | 13.71 | |
| Profit/Loss For The Period | -1.29 | 0.14 | -0.18 | 1.14 | 13.71 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | -2.97 | 0.17 | -0.23 | 1.43 | 17.14 | |
| Diluted EPS (Rs.) | -2.97 | 0.17 | -0.23 | 1.43 | 17.14 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 17.47 | 19.22 | 21.12 | 22.41 | 26.49 | |
| Indigenous Raw Materials | 81.67 | 104.75 | 101.08 | 113.39 | 81.28 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.40 | 0.80 | 1.20 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 5.00 | 15.00 |
05.03.2026
Everest Organic Standalone December 2025 Net Sales at Rs 42.59 crore, up 1.29% Y-o-Y
24.11.2025
Everest Organic Standalone September 2025 Net Sales at Rs 51.00 crore, up 15.79% Y-o-Y
10.06.2025
Everest Organic Standalone March 2025 Net Sales at Rs 40.93 crore, down 22.2% Y-o-Y
17.02.2025
Everest Organic Standalone December 2024 Net Sales at Rs 42.05 crore, down 19.91% Y-o-Y
05.03.2026
Everest Organic Standalone December 2025 Net Sales at Rs 42.59 crore, up 1.29% Y-o-Y
24.11.2025
Everest Organic Standalone September 2025 Net Sales at Rs 51.00 crore, up 15.79% Y-o-Y
10.06.2025
Everest Organic Standalone March 2025 Net Sales at Rs 40.93 crore, down 22.2% Y-o-Y
17.02.2025
Everest Organic Standalone December 2024 Net Sales at Rs 42.05 crore, down 19.91% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth